Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis

Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis

Anti-melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (MDA5-DM) is frequently complicated with rapidly progressive-interstitial lung disease (RP-ILD). The prognosis of MDA5-DM with RP-ILD is mostly poor despite intensive treatment with a combination of high-dose...

Full description

Bibliographic Details
Main Authors: Kei Ikeda, Taro Iwamoto, Shunsuke Furuta, Hiroshi Nakajima, Kotaro Suzuki, Tomoaki Ida, Kazuya Abe, Asuka Takayama, Jun Tamura, Yuki Hayashi, Syunjiro Kurihara, Junichi Ishikawa
Format: Article
Language:English
Published: BMJ Publishing Group 2023-03-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/9/1/e002795.full

Internet

https://rmdopen.bmj.com/content/9/1/e002795.full

Similar Items